Assessing the Phenotype of a Homologous Recombination Deficiency Using High Resolution Array-Based Comparative Genome Hybridization in Ovarian Cancer

• Published in: International journal of molecular sciences Vol. 24; no. 24; p. 17467
• Main Authors: Magadeeva, Svetlana, Qian, Xueqian, Korff, Nadine, Flörkemeier, Inken, Hedemann, Nina, Rogmans, Christoph, Forster, Michael, Arnold, Norbert, Maass, Nicolai, Bauerschlag, Dirk O, Weimer, Jörg P
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 14.12.2023
• Subjects: aCGH; Chromosomes; Genomes; genomic scars; Genotype & phenotype; HRD; Mutation; Ovarian cancer; PARP-inhibitor; Tumors; genomic scars; HRD; PARP-inhibitor; ovarian cancer; aCGH
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms242417467

Ovarian cancer (OC) cells with homologous recombination deficiency (HRD) accumulate genomic scars (LST, TAI, and LOH) over a value of 42 in sum. PARP inhibitors can treat OC with HRD. The detection of HRD can be done directly by imaging these genomic scars, or indirectly by detecting mutations in the genes involved in HR. We show that HRD detection is also possible using high-resolution aCGH. A total of 30 OCs were analyzed retrospectively with high-resolution arrays as a test set and 19 OCs prospectively as a validation set. Mutation analysis was performed by HBOC TruRisk V2 panel to detect HR-relevant mutations. CNVs were clustered with respect to the involved HR genes versus the OC cases. In prospective validation, the HRD status determined by aCGH was compared with external HRD assessments. Two mutation carriers did not have HRD. OC could approximately differentiate into two groups with characteristic CNV patterns with different survival rates. Mutation frequencies have a linear regression on the HRD score. Mutations in individual HR-relevant genes do not always indicate HRD. This may depend on the mutation frequency in tumor cells. The aCGH shows the genomic scars of an HRD inexpensively and directly.